The Life Science Manufacturers Association (LSMA) encompasses companies dedicated to developing, manufacturing and supplying products for R&D, diagnostic, quality control, bioproduc3on and biotechnologies. LSMA welcomes the European Commission’s ini3a3ve to streamline chemical regulations through the “One Substance One Assessment” package (2023/0453-2023/0454 and 2023/0455 (COD). This ini3a3ve aims to enhance regulatory efficiency and coherence across various chemical regulations, including REACH, RoHS, POPs, and BPR, including those relevant to life science manufacturers. However, it is crucial to ensure that the unique needs and contributions of the Life Sciences industry are adequately considered to prevent duplicative regulation and to ensure the new rules op3mise support for the EU’s health infrastructure, enhance scientific innovation and enable greater healthcare advancements. Nevertheless, we believe that the following points should be addressed
